NEW YORK, Sept. 28, 2020 /PRNewswire/ — Yesse Technologies, Inc., a New York-headquartered biotechnology company, announces the successful identification of biosensors implicated in detecting the smell associated with Parkinson’s disease and the manufacturing of its second nose-on-chip prototype developed by nanotechnology R&D partner imec, marking two important Company milestones in building the hardware to decode the sense of smell.
“Yesse Technologies has raised over $9.5M to date and has proven that the team is fit to continuously deliver on its milestones, even in the most challenging circumstances. Having the biggest technical hurdles now de-risked, we are in a perfect position to raise a Series A to take the Company to the next level,” says Dr. Charlotte D’Hulst, Co-Founder and CEO.
Through its proprietary ORion21™ genetic platform, Yesse Technologies combines the unique biology of the nose with state-of-the art silicon technology, powered by imec. Yesse Technologies’ nose-on-chip will parallel how a